enGene Holdings Inc. (ENGN) jumped 53.08% to $9.20, up $3.19, after its press release showing that its gene-therapy candidate detalimogene achieved a 62% complete response rate at six months in the Phase 2 LEGEND trial for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer.
On the day of the announcement, ENGN experienced unusually heavy trading volume as investors reacted to the data. The stock's 52-week range is $2.65 - $9.20.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.